San Diego-based MabVax Therapeutics, a biotechnology firm developing cancer treatments based on vaccine and antibody based therapies, said this morning that it has received $1.8M in a Phase 2, Small Business Innovation Research award. The award came from the National Cancer Institute. The SBIR grant is broken up into an initial grant worth $150,000, a second year award of $974,000, and a third year worth $878,000. The firm said the funding will go towards a Phase II clinical trial.
Top NewsMonday, April 11, 2011
MabVax Therapeutics Gets SBIR Grant